Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794341 | 1.00 | KMT2A (0.47) | KMT2AMEN1POLBHPGDFFAR1 | |
| SCHEMBL6785819 | 0.98 | KMT2A (0.47) | KMT2AMEN1POLBHPGDFFAR1 | |
| SCHEMBL6785816 | 0.98 | KMT2A (0.47) | KMT2AMEN1POLBHPGDFFAR1 | |
| SCHEMBL6793431 | 0.92 | KMT2A (0.53) | KMT2AMEN1POLBHPGDATM | |
| SCHEMBL6793426 | 0.92 | KMT2A (0.53) | KMT2AMEN1POLBHPGDATM | |
| SCHEMBL6786057 | 0.89 | KMT2A (0.52) | KMT2AMEN1POLBHPGDATM | |
| SCHEMBL6786060 | 0.89 | KMT2A (0.52) | KMT2AMEN1POLBHPGDATM | |
| SCHEMBL6791336 | 0.87 | KMT2A (0.50) | KMT2AMEN1POLBATML3MBTL1 | |
| SCHEMBL6791339 | 0.87 | KMT2A (0.50) | KMT2AMEN1POLBATML3MBTL1 | |
| SCHEMBL6789993 | 0.86 | KMT2A (0.48) | KMT2AMEN1POLBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | APP, PSEN1, PSEN2 | KMT2A 4348/4885MEN1 360/4885POLB 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.